NanoViricides, Inc.'s latest marketcap:
As of 07/29/2025, NanoViricides, Inc.'s market capitalization has reached $21.54 M. According to our data, NanoViricides, Inc. is the 36002th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 21.54 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -9,727,072 |
| Shares Out | 16.07 M |
| EPS (ttm) | -0.69 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/15/2025 |
NanoViricides, Inc.'s yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/29/2025 | $21.54 M | 31.71% | 36002 |
| 12/31/2024 | $20.5 M | 70.83% | n/a |
| 12/29/2023 | $12 M | -6.98% | n/a |
| 12/30/2022 | $12.9 M | -69.93% | n/a |
| 12/31/2021 | $42.9 M | 40.2% | n/a |
| 12/31/2020 | $30.6 M | 215.46% | n/a |
| 12/31/2019 | $9.7 M | -30.22% | n/a |
| 12/31/2018 | $13.9 M | -75.04% | n/a |
| 12/29/2017 | $55.7 M | -10.59% | n/a |
| 12/30/2016 | $62.3 M | -8.38% | n/a |
Company Profile
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections.
The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses.
NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Frequently Asked Questions
-
What is NanoViricides, Inc.'s (NNVC) current market cap?As of 07/29/2025, NanoViricides, Inc. (including the parent company, if applicable) has an estimated market capitalization of $21.54 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does NanoViricides, Inc. (NNVC) rank globally by market cap?NanoViricides, Inc. global market capitalization ranking is approximately 36002 as of 07/29/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.